Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Gilead Class N (ETGLX)

32.62
Net Asset Value
-0.28%
1 Day
+26.53%
Year-to-Date
Overall Morningstar Rating
Mid-cap growth
Style or Category
No Load
Sales Expenses
1.43%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Normally- the fund invests primarily in a broad range of equity securities without limitation to market capitalization. It may invest without limitation in securities in companies domiciled outside the United States either directly or through ADRs. From time to time- the fund may invest a substantial portion of its assets in the stock of companies in one or more sectors of the economy- such as the technology- industrial- healthcare and life sciences sectors.

Performance

1 month+3.56% 3 years+10.72%
3 months+7.73% 5 years+18.14%
1 year+30.79% Since inception+14.61%
Data through --

Peer Comparisonvs. Mid-cap growth

 ETGLXCategory
Performance 5-yr return+18.14%+12.62%
Expense ratio1.43%1.23%
Risk 5 year sharpe ratio1.161.07
Net assets$1.4B$1.4B
Average market cap$5.8B$11.4B
Average P/E24.528.4
Portfolio turnover26%26%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 9 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock76.49%
International stock13.45%
Cash9.65%
Fixed income0.41%
Other0.00%
Top 5 Sectors
Portfolio weighting
Hardware 23.43%
Healthcare 22.44%
Consumer goods 14.31%
Industrial materials 11.10%
Energy 7.26%
Top 10 Holdings
Portfolio weighting
XPO XPO Logistics Inc4.17%
MIC Macquarie Infrastructure Corp4.03%
BLUE bluebird bio Inc3.44%
LOW Lowe's3.20%
W Wayfair Inc3.17%
-- 2.90%
STLD Steel Dynamics Inc2.48%
WBC WABCO Holdings Inc2.38%
LRCX Lam Research Corp2.34%
ABBV AbbVie2.27%